Format

Send to

Choose Destination
Int J Hematol. 2012 Aug;96(2):164-70. doi: 10.1007/s12185-012-1121-y. Epub 2012 Jul 13.

Remission induction in acute myeloid leukemia.

Author information

1
Memorial Sloan Kettering Cancer Center, Leukemia Service, New York, NY 10065, USA.

Abstract

Inducing a complete remission (CR) in patients with acute myeloid leukemia is a prerequisite to long-term disease control with subsequent post-remission consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. The use of 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 + 3) has become the standard of care to induce CR, based on clinical trials conducted in the 1980s. Efforts to improve on the CR rate seen with the 7 + 3 regimen that translates into better overall patient survival have been disappointing. Here we review recent phase III studies of novel induction strategies that show promise in increasing the rate of CR and improving disease outcome.

PMID:
22791508
PMCID:
PMC4052975
DOI:
10.1007/s12185-012-1121-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center